Survodutide
Survodutide, a peptide. An acylated peptide dual agonist of the glucagon receptor and the GLP-1 receptor, giving GLP-1-mediated appetite and glycaemic effects plus…
An acylated peptide dual agonist of the glucagon receptor and the GLP-1 receptor, giving GLP-1-mediated appetite and glycaemic effects plus glucagon-receptor-mediated energy expenditure. Its candidate-selection paper (PMID:38560764) determined cAMP potencies in CHO-K1 cells stably expressing human GCGR and GLP-1R, but THAT ABSTRACT PRINTS NO NUMERIC EC50 OR Ki for either human receptor, so none is recorded and no occupancy row is authored. Every number that abstract does print is mouse or rat.
PubChem returns three CIDs for this name — 171378821, 168429725 and 171934786 — all with the SAME formula C192H289N47O61 and mass 4232, re-queried 2026-09-26, so the mass is unambiguous even though the entry is duplicated. At 4.2 kDa it sits in the 3-10 kDa band where this catalog's six authored volumes span 7.7-200 L and the 35 L default falls inside the spread, so the DIRECTION of the volume error is unknown and no class default would help — the record needs a real volume, not a better guess. DOSES, verbatim once-weekly subcutaneous: "subcutaneous survodutide (0.6, 2.4, 3.6, or 4.8 mg) or placebo once-weekly for 46 weeks" (PMID:38330987, phase 2 obesity); "survodutide at a dose of 2.4, 4.8, or 6.0 mg" (PMID:38847460, phase 2 MASH); and phase 3, "once-weekly survodutide administered subcutaneously at a dose adjusted up to 3.6 mg or 6.0 mg" (PMID:42253238). THE EFFICACY TRIALS CARRY NO PK AND ARE NOT CITED FOR ANY: hanging a half-life or volume on PMID:38330987, PMID:38847460 or PMID:42253238 would be the abstract-silent defect R2 documents as the FOURIER/FIELD/CLEAR pattern.
Sources: PMID:38857788, PMID:38560764, PMID:38330987, PMID:38847460, PMID:42253238